Received 3 Rare Pediatric Disease Designations (RPDD) from FDA for each of 3 potential therapies for 3 different rare inherited retinopathies ...

Jonathan Kwok, Chief Executive Officer & Co-Founder at Infinitopes, said: Using our integrated 'right targets, right vectors, right patients, right time' approach, we aim to address the unmet clinical ...

High dose TSHA-102 was generally well tolerated with no SAEs or DLTs in two adolescent/adult patients and one pediatric ...

“With our Rejuva platform, we are finalizing key in vivo studies to support the Clinical Trial Application (CTA ... RJVA-002 is a locally administered AAV9 viral vector that expresses human GIP and ...

Infinitopes' lead vaccine candidate ITOP1 is a novel, precision targeted, immunologically durable, "off-the-shelf" cancer vaccine, designed to save lives by preventing disease recurrence in first-line ...

Elizabeth Eilertsen explains how she opened a practice that aims to put patients at ease and puts their needs first.

Neurogene said it is currently evaluating other options for the NGN-101 gene therapy program, since continued investment was predicated on establishing a streamlined registrational pathway with the ...

"With our Rejuva platform, we are finalizing key in vivo studies to support the Clinical Trial Application (CTA ... RJVA-002 is a locally administered AAV9 viral vector that expresses human GIP and ...

Boston Children's Hospital and Harvard Medical School researchers have discovered a neuroimmune communication pathway that ...

Prostate cancer is the second most common cancer in men worldwide. Despite medical advances in recent years, this type of ...

Good afternoon and welcome to the Sangamo Therapeutics Third Quarter 2024 Teleconference Call. Please be advised that today's conference is being recorded. I would now like to turn the conference over ...

Passage Bio, Inc. (Nasdaq: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today reported financial results for the third ...